Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Osteoarthritis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Osteoarthritis
    TopAbstracts in Osteoarthritis 06/26/2008 - (DGNews)
    Hip Replacement Improves Function at Any Age - (DGNews)
    TopAbstracts in Osteoarthritis 06/12/2008 - (DGNews)
    TopAbstracts in Osteoarthritis 05/29/2008 - (DGNews)
    TopAbstracts in Osteoarthritis 05/15/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Osteoarthritis
      The NSAID Debate:Balancing Gastro-Protective Effects with Cardiovascular Risk
      Osteoarthritis Pain: The Role of Clinical Practice Guidelines in Evolving Treatment

      Webcasts/CME archive

       Recent cases - Osteoarthritis
        Bullet-Induced Synovitis as a Cause of Secondary Osteoarthritis of the Hip Joint: A Case Report and Review of the Literature
        Infective Discitis Mimicking Infective Endocarditis and Osteoarthritic Back Pain
        An Elderly Man with Weakness and Pain in the Thighs
        An Unusual Pattern of Osteoarthritis of the Fingers in a Nurse

        Cases archive
          




        my personal edition > osteoarthritis > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        New NIH Study Confirms that Chondroitin and Glucosamine Are Effective Against Osteoarthritis

        Information Released at ACR Annual Scientific Meeting in San Diego

        SAN DIEGO, CA -- November 16, 2005 -- The conclusion of the NIH (GAIT) Glucosamine/Chondroitin Arthritis Intervention Trial was that the combination of chondroitin sulfate and glucosamine is effective in treating moderate to severe knee pain due to ostearthritis.

        The lack of response in patients with mild pain may be due to a floor effect, limiting ability to detect response. All study agents were well tolerated.

        In his presentation today of the initial results, Dr. Daniel O. Clegg, the lead researcher in the study, indicated that while the supplements overall did not outperform the positive control, there were promising results in various sub-groups, however, he did not go into further detail at that time.

        In the presentation Dr. Clegg mentioned that NIH selected Bioiberica's chondroitin, CSb(TM)Bio-Active, as the only chondroitin used in the study. NIH Study results will be discussed in detail by Dr. Clegg at a CME lunch symposium hosted by Bioiberica on Thursday November 17th, following the ACR meeting. The role of chondroitin sulfate and its mechanisms of action and clinical response in osteoarthritis will also be discussed at this symposium.

        CSb(TM)Bio-Active is one of the most widely researched brands of chondroitin sulfate on the market. Numerous studies had shown that this natural substance is effective against osteoarthritis, which afflicts over 20 million Americans and can causes pain, stiffness, difficulty moving the afflicted joint, as well as other problems.

        In the past, some members of the medical community had downplayed the effectiveness of chondroitin sulfate, arguing that these natural substances had not been confirmed by a large-scale American clinical trial. So the NIH sponsored the Glucosamine/Chondroitin Arthritis

        Intervention Trial -- called GAIT -- to test the effectiveness of chondroitin sulfate and another popular, non-drug remedy called glucosamine as treatments for osteoarthritis.

        Twelve hundred and fifty-eight osteoarthritis patients completed this double-blind, placebo controlled study. All were 40 years of age or older and had been suffering from osteoarthritis for a mean of 10 years.

        The researchers were primarily interested in seeing whether chondroitin and/or glucosamine would reduce WOMAC scores by at least 20%. The WOMAC scale is a commonly-used method of evaluating pain and difficulty performing daily activities. The higher the WOMAC score, the greater the pain.

        The participants were divided into five different groups and given daily either 1,200mg of chondroitin sulfate, 1,500mg of glucosamine, chondroitin sulfate plus glucosamine, a positive control called Celecoxib, or a placebo.

        The results were very encouraging. Chondroitin sulfate in combination with glucosamine, not only out-performed the placebo (25%) but also Celecoxib (10%) among those patients with moderate to severe knee pain due to osteoarthritis. These results validate all the previous studies and give a lot of hope to the millions suffering from osteoarthritis.


        SOURCE: Bioiberica



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send